Paper Details

  1. Home
  2. Paper Details

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.

Author: , AntinoriAndrea, EronJoseph J, GallantJoel, HufkensVeerle, JezorwskiJohn, LathouwersErkki, MillsAnthony, MolinaJean-Michel, NegredoEugenia, OpsomerMagda, OrkinChloe, ReynesJacques, Van LanduytErika, VanveggelSimon

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg achieved a high virologic suppression rate (91.4%) and was noninferior to darunavir/cobicistat with emtricitabine/tenofovir disoproxyl fumarate (TDF) in antiretroviral-treatment-naive, HIV-1-infected adults. D/C/F/TAF demonstrated the bone and renal safety advantages of TAF in combination with darunavir/cobicistat.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: To investigate efficacy and safety of a single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg vs. darunavir/cobicistat plus emtricitabine/tenofovir disoproxyl fumarate (TDF) (control) in antiretroviral-treatment-naive, HIV-1-infec...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039393/

データ提供：米国国立医学図書館（NLM）

A New Oasis in HIV Treatment: Investigating the Efficacy of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide

In the world of HIV treatment, we're constantly searching for better, safer ways to combat this relentless disease. This research, like a compass guiding us through the vast desert of HIV, delves into the efficacy and safety of a single-tablet regimen—darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF)—in treatment-naive HIV-1 patients. The researchers conducted a large-scale, randomized, double-blind study to compare D/C/F/TAF with a standard regimen. Their findings revealed that D/C/F/TAF was noninferior to the standard regimen in achieving viral suppression. Furthermore, D/C/F/TAF demonstrated superior bone and renal safety compared to the standard regimen.

A Promising New Regimen for HIV Treatment

The results of this study are encouraging. The single-tablet regimen D/C/F/TAF achieved a high rate of viral suppression, like a well-placed oasis in the desert providing essential relief. It also exhibited a favorable safety profile, minimizing the risk of side effects. This is a significant development in HIV treatment, as it offers a convenient and effective option for patients.

The Importance of Early Intervention in HIV

This research underscores the importance of early intervention in HIV treatment. Just as a caravan needs to stop at oases along the way, patients need to access treatment as soon as possible to manage the virus and prevent long-term complications. The results of this study indicate that D/C/F/TAF is a promising option for early treatment, offering a safe and effective way to suppress the virus and improve long-term health outcomes.

Dr.Camel's Conclusion

This study marks a significant milestone in HIV treatment. The development of a single-tablet regimen that is both effective and safe is a major breakthrough. D/C/F/TAF holds great promise for improving the lives of HIV patients, offering a convenient and effective option for managing the virus and reducing the risk of complications.

Date :
  1. Date Completed 2019-10-23
  2. Date Revised 2019-10-23
Further Info :

Pubmed ID

29683855

DOI: Digital Object Identifier

PMC6039393

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.